3 unknown, 1 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 3, Completed 1 |
Follow Xiaobo Yang, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Fospropofol Disodium Versus Propofol for Deep Sedation in Critically Ill Patients Fospropofol disodium for injection, Propofol - Critical Illness | Phase 2 | Unknown | Xiaobo Yang, MD | 60 | 2023-06-01 | 2023-07-05 |
| Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation Nafamostat Mesylate, Unfractionated Heparin - Critical Illness, Anticoagulation | Phase 2 | Unknown | Xiaobo Yang, MD | 40 | 2022-12-20 | 2023-02-15 |
| Efficacy and Safety of Fospropofol Disodium Versus Propofol for Sedation in Mechanically Ventilated ICU Patients Fospropofol disodium for injection, Propofol - Critical Illness | Phase 2 | Completed | Xiaobo Yang, MD | 60 | 2022-08-10 | 2023-09-21 |
| The Effects of ECMO on the Pharmacokinetics of Hydromorphone Hydromorphone - Extracorporeal Membrane Oxygenation | Phase 2 | Unknown | Xiaobo Yang, MD | 26 | 2022-01-01 | 2024-08-06 |
Critical Illness (3)
Injections (2) · Propofol (2) · fospropofol (2) · Heparin (1) · Hydromorphone (1) · Remifentanil (1) · nafamostat (1)
China (4)